MIRA Pharmaceuticals Highlights SKNY-1's Potential in Weight Loss and Smoking Cessation

MIRA Pharmaceuticals, Inc., a clinical-stage company, has unveiled preclinical in vitro data supporting SKNY-1, a drug candidate for weight loss and smoking cessation. The data, generated by Eurofins, suggest SKNY-1's potential without causing CNS side effects. MIRA plans to acquire SKNY Pharmaceuticals, pending regulatory and shareholder approval.

SKNY-1 targets appetite, addiction, and reward pathways, avoiding psychiatric side effects that plagued earlier cannabinoid-based drugs. Eurofins' studies indicate SKNY-1 acts as a selective CB1 modulator and partial CB2 agonist, potentially affecting fat metabolism and insulin sensitivity.

SKNY-1's precision-targeting and oral administration offer a differentiated approach, avoiding issues like muscle loss associated with injectables. MIRA's acquisition of SKNY could position SKNY-1 as a significant asset in addressing obesity and nicotine addiction, with both markets poised for substantial growth.